Comparative Pharmacology
Head-to-head clinical analysis: AVZIVI versus VABYSMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVZIVI versus VABYSMO.
AVZIVI vs VABYSMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avizivi (avelumab) is a human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors. This restores anti-tumor immune responses, including T-cell activation and proliferation, by reversing PD-L1-mediated inhibition.
Vabysmo (faricimab) is a bispecific monoclonal antibody that binds to vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), inhibiting their activity. By blocking VEGF-A, it reduces endothelial cell proliferation, vascular permeability, and angiogenesis. By inhibiting Ang-2, it stabilizes blood vessels by enhancing pericyte coverage and reducing vascular leakage and inflammation.
IV 200 mg over 30 minutes on Day 1 of a 21-day cycle, in combination with paclitaxel and carboplatin; continue until disease progression or unacceptable toxicity.
Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL solution) once every 4 weeks (monthly) for 4 doses, then 6 mg every 8 weeks (2 months) thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; prolonged to 24–48 h in moderate-to-severe renal impairment.
Terminal elimination half-life: approximately 26 days (range 20–36 days) in clinical studies. This supports dosing every 8–16 weeks for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Primarily renal excretion as unchanged drug (~70%) and glucuronide conjugate (~30%); biliary/fecal excretion accounts for <5%.
Renal elimination: Vabysmo (faricimab) is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion data are available; renal elimination of intact antibody is minimal due to high molecular weight. Biliary/fecal excretion is not a major route.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor